Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - bosentan 125mg;   - film coated tablet - 125 mg - active: bosentan 125mg   excipient: ethylcellulose glyceryl behenate hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch povidone purified talc sodium starch glycolate starch titanium dioxide triacetin - tracleer® is indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.

Cingapura - inglês - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - bosentan monohydrate 129.082mg eqv bosentan - tablet, film coated - 125 mg - bosentan monohydrate 129.082mg eqv bosentan 125 mg

Cingapura - inglês - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - fluticasone propionate - aerosol, spray - 125 mcg - fluticasone propionate 125 mcg

Cingapura - inglês - HSA (Health Sciences Authority)

inova pharmaceuticals (singapore) pte. limited - theophylline anhydrous - tablet - 125 mg - theophylline anhydrous 125 mg

Cingapura - inglês - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clarithromycin - granule, for suspension - 125 mg/5 ml - clarithromycin 125 mg/5 ml

Cingapura - inglês - HSA (Health Sciences Authority)

sandoz singapore pte. ltd. - cefuroxime axetil - granule, for suspension - 125 mg/5 ml - cefuroxime axetil 125 mg/5 ml

Cingapura - inglês - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - fluticasone propionate; formoterol fumarate dihydrate - aerosol, metered - 125 mcg/actuation - fluticasone propionate 125 mcg/actuation; formoterol fumarate dihydrate 5 mcg/actuation

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - permethrin; imidacloprid - spot-on solution - 1250, 250 mg/pipette - permethrin, combinations - dogs - ectoparasiticide

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 125 mg - capsule, hard - excipient ingredients: gelatin; sodium starch glycollate type a; iron oxide yellow; silicon dioxide; magnesium stearate; titanium dioxide; iron oxide red; lactose monohydrate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.